Skip to content

Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer.

Oct 2026 · JCO Oncology Practice · pp. OP2600413 · 0 citations · 30 references
Medicine

TL;DR

Patients with metastatic PDAC spend roughly 1 in 5 days of survival engaged in health care interactions, creating substantial time toxicity-the time patients spend engaged with the health care system.

Abstract

Purpose

Optimal care for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) requires coordination across multiple providers, creating substantial time toxicity-the time patients spend engaged with the health care system. This study quantified total time toxicity and identified predictors of prolonged time toxicity in patients with metastatic PDAC.

Methods

We retrospectively analyzed patients with metastatic PDAC treated at a high-volume center from 2018 to 2022, excluding those who did not receive cancer-directed therapy or received care at multiple facilities. Time toxicity was defined as the proportion of overall survival (OS) spent in cancer-related health care encounters, with hospice time excluded. Beta regression identified predictors of time toxicity, incorporating OS as a scaling factor. Secondary outcomes included systemic therapy in the last 30 days of life, hospice transition after hospitalization, and inpatient death.

Results

Among 177 patients (median age 66 years; 57.1% male; 81.9% White), the majority received chemotherapy (n = 175) and palliative care consultation (n = 107). Median total time toxicity was 20% (IQR, 15%-28%), including 7% inpatient (IQR, 3%-16%) and 10% ambulatory (IQR, 8%-13%). Overall, 39% (n = 69) received systemic therapy in the last 30 days of life, 42.4% (n = 75) transitioned to hospice after hospitalization, and 14.8% (n = 21) died inpatient. On multivariable analysis, older age, rural/urban residence, and chemotherapy regimen predicted time toxicity (all P < .05). Each additional year of age was associated with a reduced time toxicity of 0.29%; urban residence was associated with a 3.3% increase in time toxicity compared with rural; and receiving multiple chemotherapy regimens was associated with 8.65% decrease compared with 5-fluorouracil-based regimens only.

Conclusion

Patients with metastatic PDAC spend roughly 1 in 5 days of survival engaged in health care interactions. Demographic, socioeconomic, and treatment-related factors all influence time toxicity.

View source

Similar papers

Open access Oct 2026

Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL).

289 Background: Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center. Methods: We performed a retrospective study of adults with solid organ malignancies who...

Adeel Arshad, P. Bhateja, Alyssa Antonini et al. · 0 citations
Oct 2026

Chemotherapy and immunotherapy in the final months of life: a retrospective cohort study in cancer patients.

PURPOSE Chemotherapy and immunotherapy in the palliative phase are aimed at relieving cancer symptoms and prolonging survival, but may unintentionally affect quality of life. Determining the right time to switch to a comfort orientated approach without oncolytic therapies in the palliative phase can be a challenge. We...

N. Bartels, L. Visser, D. E. Sampimon et al. · 0 citations
Open access Oct 2026

Time to Treatment Initiation and Risk of Metastatic Progression in Pancreatic Ductal Adenocarcinoma.

BACKGROUND AND OBJECTIVES The association between time to treatment initiation (TTI) and metastatic progression in pancreatic ductal adenocarcinoma (PDAC) remains poorly characterized. We evaluated the association between TTI and subsequent metastasis among patients undergoing curative-intent resection for PDAC. METH...

Abdulraheem A. Ali, Meher Angez, O. Chatzipanagiotou et al. · 0 citations
Open access Oct 2026

Assessing financial toxicity with COST-FACIT: experience from a tertiary care cancer center

Financial toxicity (FT) refers to the direct and indirect consequences of cancer diagnosis and treatment and is a key mediator of quality of life (QOL) and survival in cancer patients. To address this, financial navigation (FN) programs have been implemented in many cancer centers. At our large tertiary care cancer cen...

Mahir Khan, E. Dewey, C. Strzalka et al. · 0 citations
Open access Oct 2026

Early palliative care integration and survival outcomes in metastatic colorectal cancer: A propensity-matched analysis of a national real-world cohort.

316 Background: Early integration of palliative care is recommended for patients with advanced malignancies, yet its real-world impact in metastatic colorectal cancer (mCRC) remains incompletely characterized. We evaluated the association between the timing of palliative care referral and clinical outcomes amon...

N. Omenuko, McKenna Andrews, Angel M. Green et al. · 0 citations
Review Sep 2026

Palliative Care Support for Pediatric Cancer Patients Enrolled in Phase I Clinical Trials.

BACKGROUND Children diagnosed with cancer who enroll in phase I clinical trials may be exposed to greater risks beyond drug-related toxicity, such as delays in advance care planning and suboptimal end-of-life (EOL) care. Pediatric palliative care (PPC) can provide a specialized layer of support for patients enrolling i...

Andrea Cuviello, Mariela Trejo, Emily Zeng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.